TTK Healthcare Limited has announced that its board of directors will convene on January 22, 2026, to review and approve the company's unaudited financial results for the third quarter ended December 31, 2025. The meeting notification was issued on January 2, 2026, in compliance with regulatory requirements.

Board Meeting Details

The pharmaceutical company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda involves consideration and approval of the unaudited financial results for Q3FY26.

Trading Window Restrictions

TTK Healthcare Limited has implemented a trading window closure as part of its insider trading prevention measures. The restriction period extends from January 1, 2026, to January 24, 2026, covering both days inclusively. This measure affects all designated persons of the company and their immediate relatives, who have been specifically instructed not to trade in the company's shares during this period.

Regulatory Compliance Framework

The trading window closure follows the company's earlier communication dated December 26, 2025, which outlined the implementation of these restrictions. The measures align with the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct designed to prevent insider trading activities.

The company has formally notified both the BSE Limited and National Stock Exchange of India Limited about the scheduled board meeting and associated trading restrictions. TTK Healthcare Limited trades on BSE with scrip code 507747 and on NSE with scrip code TTKHLTCARE.

TTK Healthcare Limited has completed the transmission of shares from two deceased promoters to their legal heirs, marking the conclusion of a regulatory process that began following the deaths of key promoter group members.

Share Transmission Details

The company announced on December 29, 2025, that it has received intimation regarding the transmission of equity shares held by the deceased promoters. The transmission involves a total of 7,73,298 shares being transferred to three legal heirs:

*Minor represented by her mother and natural guardian Mrs. Maitri Gopalakrishna

Regulatory Compliance and Classification Changes

Following the transmission, TTK Healthcare has made several regulatory disclosures under SEBI LODR Regulations. Ms. Sarayu Thiruvallur Thattai will now be classified as a person belonging to the Promoter Group in accordance with Regulation 31A(6)(a).

Under Regulation 31A(6)(c), both Late Thiruvallur Thattai Jagannathan and Late Thiruvallur Thattai Venkatesh will cease to be classified as Promoter and Promoter Group members, respectively.

Updated Shareholding Pattern

The company has confirmed that the updated and accurate Promoter and Promoter Group shareholding will be reflected in the Shareholding Pattern for the quarter ending December 31, 2025. This transmission process ensures continuity in the company's ownership structure while maintaining compliance with regulatory requirements.

The completion of this transmission process represents a significant milestone in TTK Healthcare's corporate governance, providing clarity on the promoter group composition following the earlier announced deaths of the promoter group members.